Core Insights - BetterLife Pharma Inc. is focused on developing BETR-001, a non-hallucinogenic neuroplastogen aimed at treating psychiatric and neurological disorders [1][8] - BETR-001 has shown significant potential in promoting neuroplasticity, which is crucial for brain rewiring and forming new neuronal connections [2][4] - The company has received a composition of matter patent for BETR-001 and is preparing for IND filing and human trials projected for H1 2026 [7][9] Group 1: Scientific Developments - BETR-001 has been demonstrated to significantly induce the formation of new dendrites and spines in cultured rat brain cortical neurons, outperforming ketamine in these aspects [2][3] - The drug's neuroplasticity data suggests its effectiveness in treating various conditions such as depression, anxiety, PTSD, traumatic brain injury, migraines, and neuropathic pain [4][9] Group 2: Regulatory and Development Status - BetterLife has completed most of the required IND-enabling studies and has had a pre-IND meeting with the FDA [7] - The company is also developing BETR-002, which targets anxiety-related disorders, and is exploring strategic alternatives for other drug candidates [10]

BetterLife believes that BETR-001's novel mechanism of action provides a new paradigm for treatment of psychiatric disorders such as depression, anxiety and PTSD. It activates the 5HT2A receptor partially but stays below the hallucination threshold. In addition, unlike LSD, psilocybin, MDMA and other such agents BETR- 001 is not an activator of the 5HT2B receptor. Activation of 5HT2B has been linked to cardiac safety. The neuroreceptor selectivity of BETR-001 in this regard is another of its key advantages ...